EncycloReader

	Duchenne muscular dystrophy Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Duchenne muscular dystrophy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Duchenne muscular dystrophy future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Duchenne muscular dystrophy future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Duchenne muscular dystrophy future or investigational therapies
CDC on Duchenne muscular dystrophy future or investigational therapies
Duchenne muscular dystrophy future or investigational therapies in the news
Blogs on Duchenne muscular dystrophy future or investigational therapies
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Duchenne muscular dystrophy future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview[edit | edit source]

Future or investigational therapies for Duchenne muscular dystrophy include gene therapy, creatine monohydrate, myostatin inactivation, cell therapy, and idebenone (antioxidant).

Future or investigational therapies for Duchenne muscular dystrophy include:^[1]^[2]^[3]^[4]^[5]

Gene therapy
- Injecting microdystrophin genes through recombinant adeno-associated viral (rAAV) vectors
Creatine monohydrate
- Increases muscle strength
Myostatin inactivation
- Increase muscle mass and strength
Cell therapy
- Isolating and transplanting muscle satellite cells as a skeletal muscle progenitor.
Idebenone (antioxidant)

↑ Konieczny P, Swiderski K, Chamberlain JS (May 2013). "Gene and cell-mediated therapies for muscular dystrophy". Muscle Nerve. 47 (5): 649–63. doi:10.1002/mus.23738. PMC 4077844. PMID 23553671.
↑ Walter MC, Lochmüller H, Reilich P, Klopstock T, Huber R, Hartard M, Hennig M, Pongratz D, Müller-Felber W (May 2000). "Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study". Neurology. 54 (9): 1848–50. PMID 10802796.
↑ Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS (November 2002). "Functional improvement of dystrophic muscle by myostatin blockade". Nature. 420 (6914): 418–21. doi:10.1038/nature01154. PMID 12459784.
↑ Cerletti M, Jurga S, Witczak CA, Hirshman MF, Shadrach JL, Goodyear LJ, Wagers AJ (July 2008). "Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles". Cell. 134 (1): 37–47. doi:10.1016/j.cell.2008.05.049. PMC 3665268. PMID 18614009.
↑ Buyse GM, Voit T, Schara U, Straathof C, D'Angelo MG, Bernert G, Cuisset JM, Finkel RS, Goemans N, McDonald CM, Rummey C, Meier T (May 2015). "Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial". Lancet. 385 (9979): 1748–1757. doi:10.1016/S0140-6736(15)60025-3. PMID 25907158. Vancouver style error: initials (help)